Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells

Cancer Research

Volumn 63, Issue 8, 2003, Pages 1975-1980

  Bakin, Robert E ^a   Gioeli, Daniel ^a   Bissonette, Eric A ^a   Weber, Michael J ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANDROGEN; BICALUTAMIDE; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HORMONE DEPENDENCE; HORMONE SENSITIVITY; IN VITRO STUDY; MALE; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURGICAL TECHNIQUE; XENOGRAFT;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; CELL ADHESION; CELL DIVISION; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RAS PROTEINS; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037447154     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Dreicer, R. The evolving role of hormone therapy in advanced prostate cancer. Clevel. Clin. J. Med., 67: 720-722, 725-726, 2000.
2. Russell, P. J., Bennett, S., and Stricker. P. Growth factor involvement in progression of prostate cancer. Clin. Chem., 44: 705-723, 1998.
3. Foster. B. A., Kaplan, P. J., and Greenberg, N. M. Peptide growth factors and prostate cancer: new models, new opportunities. Cancer Metastasis Rev., 17: 317-324, 1998.
4. Craft, N., Shostak, Y., Carey. M., and Sawyers, C. L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med., 5: 280-285, 1999.
5. Bos, J. L. ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689, 1989.
6. Barbacid, M. ras genes. Annu. Rev. Biochem., 56: 779-827, 1987.
7. Voeller, H. J., Wilding, G., and Gelmann, E. P. v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. Mol. Endocrinol., 5: 209 -216, 1991.
8. Bakin, R., Gioeli. D., Sikes, R., Bissonette, E., and Weber, M. Constitutive activation of the Ras/MAP kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate epithelial cells. Cancer Res., in press. 2003.
9. Feldkamp, M. M., Lala, P., Lau. N., Roncari, L., and Guha, A. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery, 45: 1442-1453, 1999.
10. von Lintig, F. C., Dreilinger, A. D., Varki, N. M., Wallace, A. M., Casteel. D. E., and Boss, G. R. Ras activation in human breast cancer. Breast Cancer Res. Treat., 62: 51-62, 2000.
11. Wu. H. C., Hsieh, J. T., Gleave, M. E., Brown, N. M., Pathak, S., and Chung, L. W. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int. J. Cancer, 57: 406-412. 1994.
12. Rutter, C. M., and Elashoff, R. M. Analysis of longitudinal data: random coefficient regression modelling. Stat. Med., 13: 1211-1231. 1994.
13. Szeberenyi, J., Cai, H., and Cooper, G. M. Effect of a dominant inhibitory Ha-ras mutation on neuronal differentiation of PC12 cells, Mol. Cell. Biol., 10: 5324-5332, 1990.
14. Quilliam, L. A., Rebhun, J. F., and Castro, A. F. A growing family of guanine nucleotide exchange factors is responsible for activation of Ras-family GTPases. Prog. Nucleic Acid Res. Mol. Biol., 71: 391-444, 2002.
15. Nancy, V., Callebaut, I., El Marjou, A., and de Gunzburg, J. The delta subunit of retinal rod cGMP phosphodiesterase regulates the membrane association of Ras and Rap GTPases. J. Biol. Chem., 277: 15076-15084, 2002.
16. Murillo, H., Schmidt, L. J., and Tindall, D. J. Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2. Cancer Res., 61: 7408 -7412, 2001.
17. Lin, T. H., Chen, Q., Howe, A., and Juliano, R. L. Cell anchorage permits efficient signal transduction between ras and its downstream kinases. J. Biol. Chem., 272: 8849- 8852, 1997.
18. Lim, D. J., Liu, X. L., Sutkowski. D. M., Braun, E. J., Lee, C., and Kozlowski, J. M. Growth of an androgen-sensitive human prostate cancer cell line, LNCaP, in nude mice. Prostate, 22: 109-118, 1993.
19. Culig, Z., Hobisch, A., Bartsch, G., and Klocker, H. Androgen receptor: an update of mechanisms of action in prostate cancer. Urol. Res., 28: 211-219, 2000.
20. Culig, Z., Hobisch, A., Bartsch, G., and Klocker, H. Expression and function of androgen receptor in carcinoma of the prostate. Microsc. Res. Tech., 51: 447-455, 2000.
21. Gregory. C. W., Hamil, K. G., Kim, D., Hall, S. H., Pretlow, T. G., Mohler, J. L., and French, F. S. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res., 58: 5718-5724, 1998.
22. Visakorpi, T. New pieces to the prostate cancer puzzle. Nat. Med., 5: 264-265. 1999.
23. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., and Kallioniemi, O. P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 9: 401-406, 1995.
24. Tilley, W. D., Buchanan, G., Hickey, T. E., and Bentel, J. M. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res., 2: 277-285, 1996.
25. Taplin, M. E., Bubley, G. J., Shuster. T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., and Balk. S. P. R Mutation of the androgen -receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J., Med., 332: 1393-1398, 1995.
26. Nupponen, N., and Visakorpi, T. Molecular biology of progression of prostate cancer. Eur. Urol., 35: 351-354, 1999.
27. Hobisch. A., Culig, Z., Radmayr, C., Bartsch, G., Klocker, H., and Hittmair, A. Androgen receptor status of lymph node metastases from prostate cancer. Prostate. 28: 129-135, 1996.
28. Linja, M, J., Savinainen, K. J., Saramaki. O. R., Tammela. T. L., Vessella, R. L., and Visakorpi, T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res., 61: 3550-3555. 2001.
29. Magi-Galluzzi, C., Xu, X., Hlatky, L., Hahnfeldt, P., Kaplan, I., Hsiao, P., Chang, C., and Loda. M. Heterogeneity of androgen receptor content in advanced prostate cancer. Mod. Pathol., 10: 839-845, 1997.
30. Klocker. H., Culig. Z., Kaspar, F., Hobisch, A., Eberle, J., Reissigl, A., and Bartsch, G. Androgen signal transduction and prostatic carcinoma. World J. Urol., 12: 99-103, 1994.
31. Jenster, G. The role of the androgen receptor in the development and progression of prostate cancer. Semin. Oncol., 26: 407-421, 1999.
32. Gregory, C. W., Johnson, R. T., Jr., Mohler, J. L., French, F. S., and Wilson, E. M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res., 61: 2892-2898, 2001.
33. Gregory, C. W., He, B., Johnson. R. T., Ford, O. H., Mohler, J. L., French, F. S., and Wilson, E. M. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res., 61: 4315-4319, 2001.
34. Zegarra-Moro, O. L., Schmidt, L. J., Huang, H., and Tindall, D. J. Disruption of androgen receptor function inhibits proliferation of androgen -refractory prostate cancer cells. Cancer Res., 62: 1008-1013, 2002.
35. Eder, I. E., Hoffmann, J., Rogatsch, H., Schafer, G., Zopf, D., Bartsch, G., and Klocker, H. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther., 9: 117-125, 2002.
36. Yeh, S., Lin, H. K., Kang, H. Y., Thin, T. H., Lin, M. F., and Chang. C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA, 96: 5458-5463, 1999.
37. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr. C., Trapman, J., Hittmair. A., Bartsch. G., and Klocker, H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res., 54: 5474-5478, 1994.
38. Culig, Z., Hobisch, A., Cronauer, M. V., Hittmair, A., Radmayr, C., Bartsch, G., and Klocker, H. Activation of the androgen receptor by polypeptide growth factors and cellular regulators. World J. Urol., 13: 285-289, 1995.
39. Chen, C. D., and Sawyers, C. L. NF-κB activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer., Mol. Cell. Biol., 22: 2862-2870, 2002.
40. Yeung, F., Li, X., Ellett, J., Trapman, J., Kao, C., and Chung, L. W. Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J. Biol. Chem., 275: 40846-40855, 2000.
41. Gleave, M. E., Hsieh, J. T., Wu, H. C., von Eschenbach, A. C., and Chung, L. W. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res., 52: 1598-1605, 1992.
42. Dixon, S. C., Knopf, K. B., and Figg, W. D. The control of prostate-specific antigen expression and gene regulation by pharmacological agents. Pharmacol. Rev., 53: 73-91, 2001.
43. Davis, J. N., Muqim, N., Bhuiyan, M., Kucuk, O., Pienta, K. J., and Sarkar, F. H. Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. Int. J. Oncol., 16: 1091-1097, 2000.